Bone Biologics Announces Registered Direct Offering at Market Prices Under Nasdaq Rules
BURLINGTON, Mass., Nov. 17, 2023–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiology products for the spine fusion markets, today announced that it has entered into a definitive agreement to issue and sell a aggregate of 1,139,063 shares of common stock at a purchase price of $0.64 per share in a registered direct…
